LinKinVax has the trust of world-class partners and investors. They value our long-term prospects and our ability to use our promising biotechnology to become a leading player in a large and strategic market.
They have confidence in LinKinVax’s :
- Unique dendritic cell-targeting platform allowing rapid development of highly versatile, safe and efficient immunotherapies.
- Promising pipeline of immunotherapies including Pathogens and HPV linked Cancers.
- Scalable and reliable production model.
- Protected patent portfolio.
- Strong ties with public scientific and academic institutions.
They value our long-term prospects and our ability to use our promising biotechnology to become a leading player in a large and strategic market.
They have confidence in LinKinVax’s:
To deliver efficient vaccines for the two novel viruses discovered each year and:
LinKinVax has a binding contract with two major French public research institutions: the French National Institute for Health and Medical Research (Inserm) and the Vaccine Research Institute (VRI).
Since 2011, Inserm funded the VRI with more than 50 million euros with very encouraging results.
LinKinVax benefits from an exclusive intellectual license agreement over the entire patents portfolio of the VRI.
This unique portfolio includes more than one hundred patents covering all stages of dendritic cell vaccine development. Intellectual property is legally protected in France and worldwide.
Unlike many vaccine candidates, LinKinVax’ immunotherapy platform is based on a reliable technology: the protein vaccine. This type of vaccine has been used for over 30 years with excellent results.
This history guarantees high medical and economic safety. The medical use of proteins and antibodies is well known and documented, which allows LinKinVax to get straight to the point regarding vaccine efficiency and patient safety.
Furthermore, production is reliable thus ensuring predictable quality, volume and price.
The LinKinVax management team includes internationally-renowned medical, industrial and business expertise and is the backbone of LinKinVax’s success.
Christophe Hubert, LinKinVax’s CEO has over 25 years of international experience in Pharma and Biotech including Eli Lilly, Merck and Teva.
Pr. Yves Lévy, Founder, Chief Medical and Scientific Director, is a Professor of Clinical Immunology specializing in vaccines, is Executive Director of the Vaccine Research Institute (VRI) and former President of INSERM.
Dr. Mireille Centlivre, Founder and Chief R&D Officer, is the Chief Operating officer of VRI and has extensive research experience in HIV from The Netherlands and France.
